Insider · CIK 0002057997
Inscobee Inc.
Files at APUS (Apimeds Pharmaceuticals US, Inc.). First filing May 14, 2025, latest May 14, 2025.
In brief
Inscobee Inc. files SEC Form 4 as 10% owner at APUS (Apimeds Pharmaceuticals US, Inc.). Since May 14, 2025, Inscobee Inc. has reported 1 open-market buy worth $2.0M and 0 open-market sells worth $0, the latest filed on May 14, 2025.
A track record needs three past buys with six months of prices behind them; Inscobee Inc. has 0, so none is measured yet.
The newest scored trade: bought $2.0M of APUS on May 12, 2025, filed May 14, 2025, scored 53 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
APUS: Apimeds Pharmaceuticals US, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Apimeds Pharmaceuticals US, Inc. | $2.0M 500,000 shares | +34% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Common Stock, par value $0.01 per share | +71,090 | $2.60 | $185k | 2,055,706 | Jun 11, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Common Stock, par value $0.01 per share | +44,041 | $2.60 | $115k | 2,099,747 | Jun 11, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | Jun 11, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | Jun 11, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | POpen-market purchase Common Stock, par value $0.01 per share | +500,000 | $4.00 | $2.0M | 1,984,616 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +182,002 | $2.60 | $473k | 4,316,618 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +71,090 | $2.60 | $185k | 4,387,708 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Common Stock, par value $0.01 per share | +44,041 | $2.60 | $115k | 2,028,657 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | May 14, 2025 |
Questions about Inscobee Inc.
Answered from the filings on this page, as of the latest one.
Is Inscobee Inc. buying or selling?
Not in the last 12 months. Inscobee Inc.'s latest open-market trade on SEC Form 4 was bought $2.0M of APUS on May 12, 2025.
How did Inscobee Inc.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Inscobee Inc. has 0.
Where does Inscobee Inc. file Form 4?
Inscobee Inc. has filed Form 4 at APUS (Apimeds Pharmaceuticals US, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.